Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.

ABSTRACT:

Purpose

The National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trial demonstrated that the addition of oxaliplatin to fluorouracil plus leucovorin (FULV) improved disease-free survival (DFS) in patients with stage II or III colon cancer. This analysis is the first publication of overall survival (OS) for the NSABP C-07 study. We updated DFS and examined both end points in clinically relevant patient subsets.

Patients and methods

Other studies have identified patients age 70 or older and those with stage II disease as patient subsets in which oxaliplatin may not be effective. We investigated toxicity as a driver of divergent outcomes in these subsets.

Results

In all, 2,409 eligible patients with follow-up were randomly assigned to either FULV (FU 500 mg/m

SUBMITTER: Yothers G 

PROVIDER: S-EPMC3188282 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature